查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858269

肺炎治療市場依治療方法、給藥途徑、通路、病患年齡層、病原體類型和適應症類型分類－2025-2032年全球預測

Pneumonia Therapeutics Market by Therapy Type, Route Of Administration, Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺炎治療市場規模將成長至 338 億美元，複合年成長率為 9.26%。

主要市場統計數據
基準年 2024 166.4億美元
預計年份：2025年 181.9億美元
預測年份：2032年 338億美元
複合年成長率 (%) 9.26%

為所有相關人員提供一份全面的策略性介紹，闡述正在重新定義肺炎治療的臨床、監管和商業性趨勢。

本導言透過對當代臨床發展趨勢、不斷變化的法規環境以及正在重新定義相關利益者優先事項的不斷演進的醫療服務模式進行綜合分析，闡明了肺炎治療的現狀。該分析闡述了影響研究挑戰、產品開發策略和患者管理管道的關鍵促進因素，同時重點強調了科學創新與醫療保健系統需求之間的交集。

辨識科學創新、醫療服務模式和報銷機制的變革性轉變，這些轉變正在加速肺炎治療開發平臺的改變。

科學、醫療服務和資金籌措等各領域的變革正在匯聚，為肺炎治療開闢新的創新途徑。生技藥品和免疫調節技術的進步拓展了傳統抗感染藥物以外的治療選擇，而對病原體和宿主反應的深入研究則推動了更具針對性的研發策略。同時，醫療服務正日益分散化。門診管理、居家氧氣療法和遠距監測正在減輕住院負擔，並改變治療方法的選擇和實施方式。

分析2025年美國對肺炎治療藥物加徵關稅的累積經濟影響、供應鏈影響及臨床可近性影響。

2025年美國關稅調整的累積影響將對肺炎治療藥物的供應鏈、籌資策略和臨床取得管道產生多方面的影響。進口原料、呼吸設備組件或成品藥的關稅上調可能導致全球供應鏈分散的製造商生產成本上升、利潤率下降。這種壓力通常會導致製造商採取成本緩解措施，例如供應商多元化、關鍵組件近岸生產以及重新談判供應商契約，以維持生產的連續性和產品的可負擔性。

關鍵細分洞察揭示了治療方法類型、給藥途徑、分銷管道、患者人口統計特徵、病原體譜和適應症類別如何相互作用

一個精細化的細分框架，能夠識別不同治療方法類型、給藥途徑、分銷管道、患者群體特徵、病原體類型和適應症方面的治療方法差異化和商業性機會。治療方法類型包括輔助性治療（如皮質類固醇和霧化器）；抗感染藥物（包括抗生素、抗真菌藥物和抗病毒藥物，其中抗生素又細分為Aminoglycosides、BETA-內醯胺類、大環內酯類、奎諾酮和四環黴素）；生技藥品（包括免疫調節劑和單克隆抗體）；以及支持性治療（專注於液體管理、人工呼吸器和氧氣療法）。這些區分至關重要，因為作用機制、安全性以及所需的臨床環境決定了治療方法在從急性護理到門診護理的連續過程中所處的位置。

深入剖析美洲、歐洲、中東和非洲以及亞太地區如何影響臨床實踐、治療途徑和創新重點。

區域趨勢正顯著影響著美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、醫療服務取得以及創新療法的推廣順序。在美洲，醫療保健系統和支付方生態系統強調臨床療效和成本效益的證據，鼓勵治療方法已證實且具有顯著經濟提案的療法。此外，某些市場的過渡期照護模式和門診服務正在加速吸入和口服藥物的推廣應用，從而實現更早出院和居家照護。

公司層面的關鍵洞察，概述了領先的肺炎治療藥物開發商的策略定位、產品線差異化、合作以及商業化策略。

企業層面的發展趨勢正日益凸顯，其關注點不再侷限於單一產品的上市，而是轉向產品線差異化、策略夥伴關係和商業敏捷性。將標靶抗感染計畫與互補生物療法結合的研發企業，正致力於滿足多樣化的臨床需求，同時開闢多條驗證產品價值的途徑。許可協議和合作開發夥伴關係正被廣泛用於加速獲取互補技術，例如快速診斷和吸入給藥夥伴關係，這些技術能夠強化臨床管道並縮短產品上市時間。

行業領導者最佳化肺炎治療臨床開發、供應彈性、報銷談判和患者獲取的實用策略

業界領導者必須推動一系列切實可行、影響深遠的舉措，以在確保藥品和醫療器材可及性和可負擔性的同時，維持創新活力。首先，將衛生經濟學終點和真實世界證據收集納入試驗設計，使臨床開發項目與支付方的證據要求保持一致，將有助於促進報銷談判，並加速不同醫療機構的採用。其次，透過供應商多元化、區域製造能力和策略性庫存管理來增強供應鏈韌性，將降低貿易中斷和物流延誤對藥品和醫療設備供應的影響。

透明的調查方法，描述了肺炎治療領域評估中使用的資料來源、檢驗方法、相關利益者訪談和分析框架。

本研究採用多方面方法，結合與關鍵相關利益者的直接對話、二手文獻的綜合分析以及迭代檢驗，以確保獲得可靠的實踐見解。資料來源包括已發表的臨床文獻、監管指導文件、醫療設備和治療技術簡報、各醫療系統的採購政策以及揭示企業策略行動的公開文件。透過對臨床醫生、醫院採購負責人、生命週期管理專家和商業領域領導者的結構化訪談收集關鍵資訊，以提供關於營運挑戰和應用促進因素的具體背景。

為參與肺炎治療研發和推廣的相關人員提供策略要務、風險緩解策略和機會管道的綜合分析。

結論將分析結果提煉為策略要務，以指導各組織在肺炎治療領域尋求以病人為中心的永續解決方案。對標靶治療和支持性護理的投資必須與務實的營運策略相結合，以確保在供應鏈和貿易逆境下患者能夠獲得治療。同時，獲得強力的指南來證明其臨床和經濟價值，對於在各種醫療機構中實現廣泛應用至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 一種用於治療多重抗藥性肺炎的新型吸入式抗生素的出現
  • 監管部門核准擴大血清型覆蓋範圍，加速兒童肺炎疫苗的上市速度
  • 在醫院獲得性肺炎的治療中，生物標記指導的抗菌藥物管理通訊協定的應用日益增多。
  • 針對抗抗生素肺炎鏈球菌菌株的噬菌體療法研究投資激增
  • 將人工智慧診斷技術應用於重症肺炎病例的早期檢測與分類
  • 針對重症肺炎患者發炎路徑的單株抗體療法研發管線不斷擴大

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 肺炎治療市場：依治療方法分類

  • 輔助性治療
    • 皮質類固醇
    • 噴霧器
  • 抗感染藥物
    • 抗生素
      • Aminoglycosides
      • BETA-內醯胺類
      • 大環內酯類
      • 奎諾酮抗生素
      • 四環黴素
    • 抗真菌藥物
    • 抗病毒藥物
  • 生技藥品
    • 免疫調節劑
    • 單株抗體
  • 支持性護理
    • 點滴管理
    • 人工呼吸呼吸系統護理
    • 氧氣療法

9. 按給藥途徑分類的肺炎治療市場

  • 吸入
  • 靜脈注射
  • 口服

第10章 按分銷管道分類的肺炎治療市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 依患者年齡層別分類的肺炎治療市場

  • 成人
  • 老年人
  • 兒童

第12章 依病原體類型分類的肺炎治療市場

  • 非典型肺炎
    • 衣原體
    • 退伍軍人菌
    • 黴漿菌
  • 細菌
  • 真菌
  • 病毒性的

第13章 依適應症類型分類的肺炎治療市場

  • 社區型肺炎
  • 院內肺炎
  • 人工呼吸器相關

第14章 各地區肺炎治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 依組別分類的肺炎治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國肺炎治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Sanofi SA
    • Johnson & Johnson
    • Novartis AG
    • AstraZeneca plc
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
Product Code: MRR-8E22B61932B6

The Pneumonia Therapeutics Market is projected to grow by USD 33.80 billion at a CAGR of 9.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 16.64 billion
Estimated Year [2025] USD 18.19 billion
Forecast Year [2032] USD 33.80 billion
CAGR (%) 9.26%

Comprehensive strategic introduction to the evolving clinical, regulatory, and commercial dynamics that are redefining pneumonia therapeutics for stakeholders

The introduction establishes the current state of pneumonia therapeutics through a synthesis of contemporary clinical developments, regulatory shifts, and evolving delivery models that are redefining stakeholder priorities. This narrative frames the principal drivers shaping research agendas, product development strategies, and patient management pathways while emphasizing the intersection of scientific innovation and healthcare system needs.

By situating therapeutic advances alongside changing care environments, this opening analysis clarifies how new mechanisms of action, adjunctive care approaches, and supportive technologies are influencing clinical decision making. It also highlights the crucial role of cross-functional collaboration among clinicians, payers, manufacturers, and supply chain partners in converting scientific promise into improved patient outcomes. Transitioning from a descriptive baseline, the introduction sets up subsequent sections to explore structural shifts, regulatory and trade pressures, segmentation nuances, regional dynamics, and strategic responses that will determine near-term trajectories for pneumonia therapeutics.

Identification of transformative shifts in scientific innovation, care delivery models, and reimbursement landscapes that are accelerating change across pneumonia therapeutic pipelines

Transformative shifts across science, care delivery, and financing are converging to create new pathways for innovation in pneumonia therapeutics. Advances in biologics and immune modulation are expanding therapeutic options beyond traditional anti-infectives, while the precision characterization of pathogens and host responses is driving more targeted development strategies. At the same time, care delivery is decentralizing: outpatient management, home oxygen and remote monitoring reduce inpatient burden and change how therapies are chosen and delivered.

Concurrently, payer and reimbursement models increasingly reward clinical outcomes and value-based approaches, which pressures developers to demonstrate differentiated benefits beyond pathogen clearance. Digital health tools and real-world evidence are being integrated into regulatory and reimbursement dialogues, accelerating adaptive trial designs and post-approval evidence generation. As a result, scientific innovation, care model evolution, and financing mechanisms are collectively reshaping prioritization across discovery, clinical development, and commercialization, requiring integrated strategies that balance efficacy, access, and economic sustainability.

Analysis of the cumulative economic, supply chain, and clinical access implications stemming from United States tariff actions in 2025 for pneumonia therapeutics

The cumulative effects of tariff adjustments enacted by the United States in 2025 create a multi-dimensional impact on pneumonia therapeutic supply chains, procurement strategies, and clinical access pathways. Increased duties on imported raw materials, components for respiratory devices, or finished pharmaceuticals can raise production costs and compress margins for manufacturers whose supply chains are globally distributed. This pressure often prompts cost mitigation responses such as supplier diversification, nearshoring of critical components, and renegotiation of supplier contracts to preserve manufacturing continuity and product affordability.

Beyond direct cost effects, tariffs can alter logistics and lead times for critical inputs such as APIs, single-use device components, and specialized medical equipment used in oxygen therapy and mechanical ventilation. These disruptions have downstream clinical implications when hospitals and procurement teams encounter variability in availability or elevated pricing that affects formulary decisions and stocking policies. Moreover, tariff-driven changes incentivize stronger supplier qualification processes, increased inventory buffers, and strategic stockpiling for critical items. In parallel, payers and health systems may intensify scrutiny of total cost of care, accelerating shifts toward therapeutics and delivery models that demonstrate durable clinical and economic value. In aggregate, the 2025 tariff dynamics pressure manufacturers to redesign supply networks and strengthen commercial arguments for value and access while health systems adapt procurement strategies to maintain clinical readiness.

Critical segmentation insights revealing how therapy types, administration routes, distribution channels, patient age cohorts, pathogen profiles, and indication categories interact

A nuanced segmentation framework illuminates where therapeutic differentiation and commercial opportunity intersect across therapy type, administration route, distribution channel, patient age group, pathogen type, and indication. Therapy type spans adjunctive therapies that include corticosteroids and device-based nebulizers, anti-infectives composed of antibiotics, antifungals, and antivirals with antibiotics further detailed into aminoglycosides, beta lactams, macrolides, quinolones, and tetracyclines, biologics that encompass immune modulators and monoclonal antibodies, and supportive therapies oriented around fluid management, mechanical ventilation, and oxygen therapy. These distinctions matter because mechanism of action, safety profiles, and required clinical settings determine where a therapy sits along the acute care to outpatient continuum.

Route of administration-covering inhalation, intravenous, and oral delivery-directly affects adherence, ease of outpatient management, and the complexity of supply logistics. Distribution channels ranging from hospital pharmacy to online and retail pharmacy shape go-to-market approaches, pricing strategies, and patient access pathways. Patient age groups, including adult, geriatric, and pediatric cohorts, demand tailored safety and dosing strategies and influence trial design and labeling priorities. Pathogen type segmentation, which includes atypical organisms subdivided into Chlamydophila, Legionella, and Mycoplasma, as well as bacterial, fungal, and viral causes, drives diagnostic requirements and targeted therapeutic development. Finally, indication type such as community acquired, hospital acquired, and ventilator associated pneumonia creates distinct clinical management algorithms, differing regulatory expectations, and variable pathways to adoption. Collectively, this segmentation matrix provides a roadmap for aligning R&D focus, clinical trial populations, and commercialization plans with unmet needs and operational realities.

In-depth regional insights on how Americas, Europe Middle East and Africa, and Asia-Pacific are each shaping clinical practice, access pathways, and innovation priorities

Regional dynamics exert a strong influence on clinical practice patterns, access to therapeutics, and the sequencing of innovation adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems and payer ecosystems emphasize evidence of clinical benefit and cost-efficiency, which incentivizes therapeutics with demonstrable outcomes and robust economic value propositions. Transitional care models and outpatient capabilities in certain markets also accelerate adoption of inhaled and oral regimens that facilitate earlier discharge and home-based care.

Europe, Middle East & Africa present heterogenous regulatory and reimbursement landscapes where centralized guidelines coexist with national-level variations in uptake and procurement. This mosaic drives the need for flexible regulatory strategies, regionally tailored clinical evidence packages, and differentiated pricing approaches. Asia-Pacific encompasses a spectrum from highly sophisticated healthcare markets to rapidly developing systems where access, local manufacturing capacity, and public health priorities shape adoption. Across these regions, differences in pathogen prevalence, diagnostic infrastructure, and hospital capacity influence the relative demand for biologics, targeted anti-infectives, and supportive technologies. Taken together, these regional characteristics require companies to deploy tailored regulatory engagement, supply planning, and evidence generation strategies that align with local clinical practices and procurement frameworks.

Key company-level insights outlining strategic positioning, pipeline differentiation, collaborative ventures, and commercialization strategies across leading pneumonia therapeutics developers

Company-level dynamics are increasingly defined by a focus on pipeline differentiation, strategic partnerships, and commercialization agility rather than singular product launches. Developers that combine targeted anti-infective programs with adjunctive biologic approaches position themselves to address heterogeneous clinical needs while creating multiple levers for value demonstration. Licensing agreements and co-development partnerships are commonly used to accelerate access to complementary technologies, such as rapid diagnostics or inhalation delivery platforms, that strengthen clinical adoption pathways and improve time-to-market execution.

At the commercial interface, companies are investing in evidence generation beyond pivotal trials, emphasizing real-world data collection, health economics and outcomes research, and post-authorization safety monitoring to meet payer and clinician expectations. Manufacturing strategies are evolving to incorporate dual-sourcing and regional production capacity for critical inputs and devices to mitigate supply interruptions. Finally, corporate strategies increasingly reflect a blend of selective M&A to secure complementary capabilities, targeted geographic expansion to capture access opportunities, and flexible commercial models that support hospital procurement teams and community providers in diverse settings.

Actionable strategic recommendations for industry leaders to optimize clinical development, supply resilience, reimbursement engagement, and patient access for pneumonia care

Industry leaders must pursue a set of pragmatic, high-impact actions to sustain innovation while safeguarding access and affordability. First, aligning clinical development programs with payer evidence requirements by embedding health economic endpoints and real-world evidence collection into trial designs will facilitate reimbursement discussions and accelerate uptake in diverse healthcare settings. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing capacity, and strategic inventory management will reduce vulnerability to trade disruptions and logistic delays that affect both drug and device availability.

Third, companies should cultivate integrated partnerships with diagnostics providers and care delivery organizations to enable precision targeting of therapies and to support outpatient and home-based care models. Fourth, commercial strategies must balance tiered pricing and contracting flexibility with transparent value communication to hospitals, payers, and pharmacy channels. Fifth, embedding digital tools for adherence support, remote monitoring, and patient engagement can improve outcomes and create measurable value for health systems. By implementing these coordinated actions, organizations can simultaneously advance clinical innovation, reinforce access pathways, and create defensible commercial positions in a fragmented and rapidly evolving therapeutic landscape.

Transparent research methodology explaining data sources, validation approaches, stakeholder interviews, and analytical frameworks employed in assessing pneumonia therapeutic areas

This research employed a multi-method approach combining primary stakeholder engagement, secondary literature synthesis, and iterative validation to ensure robust, actionable insights. Data sources included published clinical literature, regulatory guidance documents, device and therapeutic technical briefs, procurement policies from diverse health systems, and public filings that illuminate strategic company behavior. Primary inputs were gathered through structured interviews with clinicians, hospital procurement specialists, lifecycle management experts, and commercial leaders who provided contextual detail on operational challenges and adoption drivers.

Analytical frameworks integrated qualitative thematic analysis with scenario mapping to identify risk factors and opportunity pathways across clinical, supply chain, and reimbursement dimensions. A validation layer reconciled conflicting signals by triangulating interview findings with documented regulatory precedents and technical specifications of devices and drug classes. Throughout the process, emphasis was placed on transparency in assumptions, traceability of evidence, and the reproducibility of key conclusions, ensuring that recommendations are grounded in observable practice and validated stakeholder perspectives.

A concluding synthesis that distills strategic imperatives, risk mitigations, and opportunity pathways for stakeholders engaged in pneumonia therapeutic development and delivery

The conclusion synthesizes the analysis into a set of strategic imperatives that guide organizations toward durable, patient-centered solutions in pneumonia therapeutics. Investment in targeted therapeutics and supportive care modalities must be paired with pragmatic operational strategies that preserve access amid supply chain and trade headwinds. Simultaneously, robust evidence generation that demonstrates clinical and economic value will be decisive in achieving broad adoption across varied care settings.

Risk mitigation requires proactive supply chain redesign, stronger partnerships across diagnostics and care delivery, and adaptable commercial approaches that respect regional heterogeneity. Opportunity lies in integrating diagnostics-driven therapeutics, expanding outpatient care capabilities, and leveraging digital health to enhance adherence and monitoring. Collectively, these imperatives form a coherent agenda for stakeholders seeking to advance therapeutic innovation while ensuring that clinical gains translate into measurable improvements in patient outcomes and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of novel inhalable antibiotic formulations for multidrug resistant pneumonia treatment
  • 5.2. Regulatory approvals accelerating availability of pediatric pneumonia vaccines with expanded serotype coverage
  • 5.3. Rising adoption of biomarker-guided antibiotic stewardship protocols in hospital acquired pneumonia management
  • 5.4. Investment surge in phage therapy research targeting antibiotic resistant Streptococcus pneumoniae strains
  • 5.5. Integration of artificial intelligence diagnostics for early detection and classification of severe pneumonia cases
  • 5.6. Growing pipeline of monoclonal antibody therapies targeting inflammatory pathways in severe pneumonia patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumonia Therapeutics Market, by Therapy Type

  • 8.1. Adjunctive Therapies
    • 8.1.1. Corticosteroids
    • 8.1.2. Nebulizers
  • 8.2. Anti Infectives
    • 8.2.1. Antibiotics
      • 8.2.1.1. Aminoglycosides
      • 8.2.1.2. Beta Lactams
      • 8.2.1.3. Macrolides
      • 8.2.1.4. Quinolones
      • 8.2.1.5. Tetracyclines
    • 8.2.2. Antifungals
    • 8.2.3. Antivirals
  • 8.3. Biologics
    • 8.3.1. Immune Modulators
    • 8.3.2. Monoclonal Antibodies
  • 8.4. Supportive Therapies
    • 8.4.1. Fluid Management
    • 8.4.2. Mechanical Ventilation
    • 8.4.3. Oxygen Therapy

9. Pneumonia Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Pneumonia Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Pneumonia Therapeutics Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Pneumonia Therapeutics Market, by Pathogen Type

  • 12.1. Atypical
    • 12.1.1. Chlamydophila
    • 12.1.2. Legionella
    • 12.1.3. Mycoplasma
  • 12.2. Bacterial
  • 12.3. Fungal
  • 12.4. Viral

13. Pneumonia Therapeutics Market, by Indication Type

  • 13.1. Community Acquired
  • 13.2. Hospital Acquired
  • 13.3. Ventilator Associated

14. Pneumonia Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Pneumonia Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pneumonia Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. GlaxoSmithKline plc
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Sanofi S.A.
    • 17.3.5. Johnson & Johnson
    • 17.3.6. Novartis AG
    • 17.3.7. AstraZeneca plc
    • 17.3.8. Bayer AG
    • 17.3.9. Teva Pharmaceutical Industries Ltd.
    • 17.3.10. Dr. Reddy's Laboratories Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PNEUMONIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN